Catalog No.
Product Name
Application
Product Information
Citations
-
Bioactive Peptide
CFP10 (71–85) is a bioactive peptide that stimulates the production of interferon-gamma (IFN-γ) and enhances cytotoxic T lymphocyte (CTL) activity in both CD4+ and CD8+ T cells. It is particularly effective in individuals expressing various MHC class II and class I molecules. This peptide is valuable for research applications focused on immune response modulation and T cell activation. -
EpCAM/CD3 Bispecific Antibody
M701 is a bispecific humanized antibody that targets epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). By binding to EpCAM on tumor cells and CD3 on T cells, M701 effectively links these two cell populations, facilitating targeted cytotoxicity and enhancing T cell-mediated immune responses. This reagent is particularly valuable for research focused on advanced epithelial solid tumors, aiding in the development of innovative therapies. -
Anti-CD3E Antibody
Ebribafusp alfa is an anti-CD3E IgG4κ chimeric antibody designed to modulate immune responses by targeting the CD3 epsilon subunit of the T cell receptor complex. This compound exhibits potential therapeutic activity in autoimmune diseases and T cell-related conditions by enhancing T cell-mediated immunity. Research applications include investigations into T cell activation and modulation strategies in immunotherapy and transplant biology. -
Anti-CD3E/CD4 Antibody
Amtabafusp alfa is a humanized IgG1 λ1 antibody that targets CD3E and CD4. This recombinant antibody is designed for applications in immunology and cancer research, facilitating the study of T cell activation and tumor microenvironment interactions. It serves as a crucial tool for investigating immune responses and therapeutic strategies in various diseases. -
Anti-FOLH1/PSMA And CD3E Antibody
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody that targets FOLH1/PSMA and CD3E. This reagent effectively binds to the prostate-specific membrane antigen (PSMA) on tumor cells and to CD3E on T cells, leading to significant T cell activation. Olsutamig is primarily employed in research focused on immuno-oncology, particularly for its potential to selectively induce apoptosis in prostate cancer cells through T cell-mediated mechanisms. -
CD38 Inhibitor
CVN14 is a selective and potent inhibitor of CD38, exhibiting inhibitory activity with human and mouse IC50 values of 19 nM and 2.4 nM, respectively. This compound binds uncompetitively to CD38, forming a complex with ADPR and subsequently inhibiting its enzymatic activity. CVN14 is suitable for research applications focused on neurodegenerative diseases, providing insights into the role of CD38 in these conditions. -
CD38 Inhibitor
Luteolinidin chloride is a potent inhibitor of CD38, with a Ki value of 11.4 μM, and demonstrates significant antioxidant activity. This compound has shown to protect cardiac tissue from ischemia/reperfusion injury by preserving the functionality of endothelial nitric oxide synthase (eNOS) and preventing endothelial dysfunction. Additionally, Luteolinidin chloride acts as a competitive inhibitor of tyrosinase, with an IC50 of 3.7 μM, effectively blocking melanin production. This makes it a valuable reagent for research in cardiovascular protection and skin pigmentation studies. -
Anti-CD38 mAb/IFNα2b Fusion Protein
Modakafusp alfa is a humanized anti-CD38 IgG4 monoclonal antibody fused with two attenuated interferon-alpha 2b molecules, targeting CD38-expressing cells. It exhibits direct anti-proliferative activity against multiple myeloma cells in vitro and elicits significant and sustained antitumor responses in xenograft tumor models. Additionally, the combination of Modakafusp alfa with anti-PD-1 antibodies promotes immunomodulation and enhances antitumor efficacy, demonstrating a favorable tolerance profile in murine models. This reagent is valuable for research in multiple myeloma therapy and immune checkpoint modulation. -
CD38 Inhibitor
CD38 Inhibitor 2 is a selective inhibitor of CD38 with an IC50 range of 0.01 to 0.1 μM. This compound demonstrates potent inhibition of CD38 enzymatic activity, making it a valuable tool for studies focused on NAD+ metabolism and immune regulation. Its applications extend to cancer research, immunology, and age-related studies, contributing to a better understanding of the role of CD38 in various biological processes. -
CD38 Inhibitor
Ara-F-NAD+ is an arabino analogue of NAD+ and functions as a potent, reversible, and slow-binding inhibitor of CD38 NADase. This compound effectively modulates NAD+ metabolism, making it a valuable tool for studying the role of CD38 in various biological processes. Ara-F-NAD+ has potential applications in research focused on immune regulation, cellular signaling, and metabolic disorders related to NAD+ homeostasis. -
Anti-CD38 Antibody
Sanritatug is a humanized IgG1κ antibody that specifically targets CD38, a cell surface protein involved in immune regulation and metabolism. This antibody has demonstrated significant potential in modulating immune responses and is being investigated for therapeutic applications in various hematological malignancies and autoimmune diseases. Sanritatug may aid in the exploration of CD38's role in disease pathophysiology and the development of targeted immunotherapies. -
CD38 Inhibitor
6-Alkyne-F-araNAD is an irreversible inhibitor of CD38, a critical enzyme involved in the regulation of cyclic ADP-ribose and NAD metabolism. This compound enhances the efficacy of fluorescent probes, such as SR101-F-araNMN, allowing for improved visualization of intracellular CD38 localization. It serves as a valuable tool in studies related to immune signaling and cellular response mechanisms. -
CD38 Hydrolase Inhibitor
CD38-IN-5 is a selective inhibitor of CD38 hydrolase, exhibiting an IC50 of 4.0 μM, while sparing CD38 cyclase activity. This compound is particularly effective in enhancing natural killer (NK) cell-mediated tumor cytotoxicity and promotes increased levels of NADH+ and IFNγ in activated peripheral blood mononuclear cells (PBMCs). CD38-IN-5 serves as a valuable tool for cancer research, facilitating the investigation of immune modulation and tumor interactions. -
CD38 Inhibitor
(E/Z)-CCR-11 is a selective inhibitor of CD38, exhibiting an IC50 value of 20.8 μM against CD38 cyclase. This compound effectively enhances cellular NAD+ levels and promotes the production of interferon γ. It is valuable for research applications focused on cellular metabolism and immune response modulation. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 2 is an inhibitor that targets the interaction between Hyaluronic acid (HA) and CD44. It exhibits antiproliferative effects on CD44-positive cancer cells, effectively disrupting cancer sphere integrity and decreasing cell viability in a dose-dependent manner. This compound is suitable for applications in tumor research aimed at understanding the role of CD44 in cancer progression. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 1 is a specific inhibitor of the interaction between hyaluronic acid (HA) and CD44. By disrupting this interaction, it demonstrates significant antiproliferative effects on CD44+ cancer cell lines. This compound is valuable for research aimed at understanding cancer progression and potential therapeutic strategies targeting CD44-mediated cellular processes. -
CD47 Inhibitor
Evorpacept is a high-affinity CD47 inhibitor designed to block the CD47-SIRPα immune checkpoint interaction. By binding to CD47, Evorpacept facilitates the inhibition of wild-type SIRPα binding, enhancing immune response against tumors. This reagent is particularly relevant for research applications focused on acute myeloid leukemia and other malignancies where CD47 plays a pivotal role in immune evasion. -
CD47 Fusion Protein
Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy. -
Anti-MS4A1/CD47 Antibody
Amulirafusp alfa is an anti-MS4A1/CD47 IgG1κ type human antibody designed to target the MS4A1/CD47 axis. This antibody exhibits key biological activity by antagonizing CD47-mediated immune evasion, thereby enhancing phagocytosis and promoting anti-tumor immunity. It is suitable for applications in cancer immunotherapy research and studies exploring immune cell interactions in various disease models. -
Anti-CD47 Antibody
TQB-2928 is a monoclonal antibody targeting CD47, a prominent regulator of immune evasion in cancer cells. This reagent plays a crucial role in research focused on cancer immunotherapy by blocking the "don't eat me" signal that CD47 transmits to macrophages. TQB-2928 is essential for studying tumor microenvironments, immune responses, and developing therapeutic strategies aimed at enhancing anti-tumor immunity. -
CD47/SIRPα blocking peptide
Pep-20 is a CD47/SIRPα blocking peptide that inhibits the interaction between CD47 and SIRPα, demonstrating KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. With IC50 values of 24.56 μM and 12.03 μM, respectively, for blocking these interactions, Pep-20 exhibits significant anti-tumor activity. This peptide is useful in research applications focused on immune evasion in cancer therapies and interactions within the tumor microenvironment. -
CD47/SIRPα Blocker
NCGC00138783 free base is a selective blocker of the CD47/SIRPα interaction, exhibiting an IC50 of 50 µM. By inhibiting this axis, NCGC00138783 free base promotes immune cell activation, making it a valuable tool for research in cancer immunotherapy and immune modulation studies. Its ability to disrupt CD47 signaling can facilitate investigations into tumor evasion mechanisms and potential therapeutic strategies. -
CD47 Monoclonal Antibody
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody that targets the CD47-SIRPα interaction to induce tumor phagocytosis. This antibody preferentially binds to tumor cells over normal cells and promotes tumor cell death through a direct mechanism, independent of antibody-dependent cell-mediated cytotoxicity (ADCC). AO-176 exhibits dose-dependent antitumor effects in tumor xenograft models, making it a valuable tool for cancer research, particularly in studies involving lymphoma. -
CD73 Inhibitor
CD73-IN-5 is a potent and selective small molecule inhibitor of CD73, exhibiting an IC50 value of 19 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the production of adenosine in the tumor microenvironment. CD73-IN-5 is utilized in research applications exploring immunomodulation, cancer therapy, and the therapeutic potential of targeting adenosine signaling pathways. -
CD73 Inhibitor
CD73-IN-4 is a selective inhibitor of CD73, functioning through the blockade of adenosine production. With an IC50 of 2.6 nM against human CD73, it demonstrates significant potency in modulating immunosuppressive signals in the tumor microenvironment. This compound is valuable for investigating cancer immunology and exploring therapeutic strategies aimed at enhancing anti-tumor immune responses. -
CD73 Inhibitor
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. By blocking adenosine production, OP-5244 effectively reverses immunosuppression, making it a valuable tool in cancer research. Its application can aid in the exploration of therapeutic strategies aimed at enhancing anti-tumor immunity. -
Anti-CD73/TGF-β Antibody
Dalutrafusp alfa is a bifunctional antibody that targets CD73 and TGF-β, key components involved in the immunosuppressive pathway. This compound modulates immune responses by inhibiting adenosine production and blocking TGF-β signaling. It is primarily utilized in research focused on tumor immunology and the modulation of immune checkpoints. Its unique mechanism allows for exploration in various therapeutic applications, particularly in cancer treatment and autoimmune diseases. -
NTPDase1 Inhibitor
8-BuS-AMP is an inhibitor of NTPDase1, CD73, and CD39, demonstrating an IC50 of 35 μM and a Ki of 0.292 μM for human NTPDase1, alongside Ki values of 1.19 μM for CD73 and 0.847 μM for CD39. This compound interacts with the substrate-binding sites of NTPDase1 and CD73, effectively preventing the conversion of ATP and AMP to adenosine, which promotes the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP exhibits robust enzymatic hydrolysis resistance and metabolic stability, and it has no activity against P2Y1 and P2Y12 receptors. This reagent is suitable for investigations into purinergic signaling pathways and cancer research. -
CD73 Inhibitor
ORIC-533 is a selective, orally active inhibitor of CD73 that operates through an AMP-competitive mechanism, demonstrating potent inhibition of adenosine production with a sub-nanomolar affinity (Ka 0.03 nM). This compound has shown significant promise in the context of multiple myeloma, as it enhances the cytotoxic activity of the immune system against tumor cells by reversing immunosuppression, inducing immunogenic cell death, and activating various immune cells including dendritic cells, T cells, and NK cells, while exhibiting minimal toxicity to normal cells. Furthermore, combined administration of ORIC-533 with daratumumab effectively increases intratumoral CD8+ T cell infiltration and substantially inhibits tumor growth in preclinical models. -
CD73 Inhibitor
CD73-IN-11 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP into adenosine. By inhibiting CD73, this compound disrupts adenosine production, which is known to induce immunosuppressive effects and can promote tumor proliferation and metastasis. CD73-IN-11 is an essential tool for studying tumor-related diseases and investigating the role of adenosine in cancer biology. -
CD73 Inhibitor
CD73-IN-2 is a potent inhibitor of CD73, demonstrating an IC50 value of 0.09 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the regulation of extracellular adenosine levels. CD73-IN-2 is valuable for research applications focused on immuno-oncology, inflammation, and metabolic diseases. -
CD73 Inhibitor
CD73-IN-19 is a potent CD73 inhibitor, exhibiting a 44% inhibition of CD73 enzymatic activity at 100 μM. It effectively counteracts TCR-induced blockade of T cell proliferation at concentrations of 10 μM and 100 μM, highlighting its role in modulating immune responses. Additionally, CD73-IN-19 has been shown to inhibit hA2A receptor activity in HEK-293 cells, with a Ki value of 3.31 μM. This compound demonstrates potential value in studies related to immune disorders and therapeutic interventions. -
CD73 Inhibitor
CD73-IN-10 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. By inhibiting CD73, this compound can reduce the immunosuppressive effects of adenosine, which play a role in tumor proliferation and metastasis. CD73-IN-10 is valuable for research applications focused on tumor biology and the study of tumor-related diseases. -
CD73 Inhibitor
CD73-IN-13 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool in the investigation of tumor-related diseases, offering insights into the biochemical pathways associated with cancer progression. Researchers can utilize CD73-IN-13 to explore the therapeutic potential of targeting CD73 in various malignancies. -
CD73 Inhibitor
CD73-IN-8 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP to adenosine. Elevated levels of adenosine are associated with immunosuppression and enhanced tumor growth and metastasis. CD73-IN-8 is valuable for investigating tumor-related diseases and exploring therapeutic strategies aimed at modulating the adenosine pathway in cancer research. -
CD73 Inhibitor
CD73-IN-14 is a potent and selective inhibitor of CD73, exhibiting an IC50 of 0.17 nM. This compound enhances the recruitment of tumor-infiltrating CD8+ T cells and demonstrates significant anti-tumor activity. Additionally, CD73-IN-14 features an alkyne group that enables its use in click chemistry applications, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing partners. This reagent is valuable for studies in immuno-oncology and chemical biology, allowing for the exploration of immune modulation and therapeutic strategies. -
CD73 Inhibitor
ZM522 is a potent CD73 inhibitor with an IC50 value of 0.56 μM. This compound enhances immune activity by elevating interferon-γ (INF-γ) levels and modulating T cell activation. ZM522 is suitable for research applications in immunology and cancer therapy, offering potential insights into immune response mechanisms and therapeutic strategies. -
CD73 Inhibitor
MethADP trisodium is a potent inhibitor of CD73, targeting the enzymatic conversion of ATP to adenosine. This compound plays a crucial role in studies investigating the ATP-adenosine signaling pathway and its implications in cancer, immunology, and inflammatory diseases. MethADP trisodium is instrumental for researchers exploring the modulation of adenosine levels and the effects on immune cell function. -
CD73 Inhibitor
MRS4620 is a potent inhibitor of CD73, exhibiting an inhibitory constant (Ki) of 0.436 nM. This compound is primarily utilized in cancer immunology research, where it can help elucidate the role of CD73 in immune regulation and tumor microenvironment modulation. MRS4620 is valuable for studies aimed at enhancing anti-tumor immunity and understanding the mechanisms of immune evasion in cancer. -
CD73 Inhibitor
CD73-IN-9 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Elevated adenosine levels are associated with immunosuppressive effects and can promote tumor proliferation and metastasis. This compound is valuable for investigating tumor-related diseases and understanding the role of CD73 in cancer biology. -
OTUD4/CD73 Inhibitor
ST80 is an inhibitor of the OTUD4/CD73 interaction. It effectively decreases the protein level of CD73 and enhances its turnover, which reduces the immune evasion capabilities of tumor cells. This results in significant antitumor efficacy, particularly in the context of immunosuppressive triple-negative breast cancer (TNBC), making ST80 valuable for research in cancer immunotherapy. -
CD73 Inhibitor
PSB-0963 is a selective and competitive inhibitor of ecto-5'-nucleotidase (eN or CD73), exhibiting an inhibition constant (Ki) of 150 nM for rat ecto-5'-nucleotidase. This compound demonstrates high selectivity for eN/CD73 over other ectonucleotidases, such as NTPDases 1-3, and P2Y receptors. PSB-0963 is valuable for research involving cancer biology, particularly in studies focused on immune regulation and tumor microenvironment interactions. -
CD73 Inhibitor
CD73-IN-12 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool for investigating tumor-related diseases and their underlying mechanisms. Additionally, CD73-IN-12 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it useful for click chemistry applications in biochemical research. -
CD73 Inhibitor
CD73-IN-18 is a potent inhibitor of extracellular 5-nucleotidase (CD73). By blocking CD73 activity, this compound has shown potential in anti-cancer research, enhancing immune responses against tumors. It serves as a valuable tool in studies aimed at understanding tumor microenvironments and developing novel cancer therapies. -
CD73 Inhibitor
CD73-IN-6 is a potent inhibitor of CD73, a key enzyme involved in the adenosine pathway. This compound is essential for investigating the role of CD73 in cancer biology and its potential therapeutic applications. CD73-IN-6 can be utilized in research focused on tumor immunology and the modulation of the tumor microenvironment, providing insights into cancer progression and treatment strategies. -
CD73 Inhibitor
CD73-IN-7 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Adenosine plays a critical role in immunosuppression and can facilitate tumor proliferation and metastasis. CD73-IN-7 is suitable for research applications focused on tumor biology and the modulation of immune responses in cancer. -
CD73 Inhibitor
MethADP disodium is a specific inhibitor of CD73, an enzyme involved in the regulation of adenosine signaling. By inhibiting CD73 activity, MethADP disodium can impede the production of adenosine, which plays a critical role in immune suppression and tumor progression. This compound is useful for research applications focusing on cancer immunotherapy, inflammation, and metabolic diseases, providing insights into the modulation of the adenosine pathway. -
CLIP Fragment
CLIP (86-100) is the amino acid fragment of the class II-associated invariant chain peptide, comprising residues 86 to 100. This small self-peptide is a cleavage product that resides within the HLA-II antigen binding groove, playing a pivotal role in the assembly and transport of MHC class II alphabetaIi complexes. It interacts with the class II peptide-binding site, making it essential for understanding MHC class II functionality in immunological research and potential therapeutic applications. -
Anti-Complement C5 Antibody
Ascuprubart is a monoclonal antibody specifically designed to target human Complement C5. By inhibiting the activity of C5, this antibody plays a crucial role in modulating the complement pathway, making it instrumental in research related to immune response and inflammation. Ascuprubart is suitable for applications in studies focused on complement-mediated diseases and therapeutic development. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer.
